FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 

Has this patient's data been previously reported to USIDNET?

  
 nmlkji

yes  
 nmlkji

no  

 
 
USIDNET ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type: (check all that apply) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type: (check all that apply) 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

Visit:

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 
Specify:    

 
 
1  Date of most recent hematologic testing: __ __ __ __ - __ __- __ __  

 
 
2    

gfedcb
WBC not tested

  
 
WBC:    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
3    

gfedcb
Lymphocytes not tested

 
 
Lymphocytes:    % 

 
 
4    

gfedcb
Eosinophils not tested

 
 
Eosinophils:    % 

 
 
5    

gfedcb
Polymorphonuclear leukocytes (PMN) not tested

 
 
Polymorphonuclear leukocytes (PMN):    % 

 
 
6    

gfedcb
Hemoglobin not tested

  
 
Hemoglobin:    

 

 nmlkji
g/dL  

 nmlkji
g/L  

 nmlkji
mmol/L  

 
 

  
gfedcb

transfused RBC < 30 days from date of most current testing

 
 
7    

gfedcb
Platelets not tested

  Key Fields 

Laboratory Studies Post-HSCT Questions: 1 - 43

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 12



  
 
Platelets:    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

transfused platelets < 7 days from date of most current testing

 

Immunoglobulin Analysis 

Specify the most recent quantitative immunoglobulins measured since the date of the last report. 

For questions 8–13, also report immunoglobulins in the Form 2100 – 100 Days Post-HSCT Data beginning at question 55, or in the Form 2200 — Six Months to Two Years 
Post-HSCT Data beginning at question 26. 

For questions 16–17, also report IVIG in the Form 2100 – 100 Days Post-HSCT Data beginning at question 61, or in the Form 2200 — Six Months to Two Years Post-HSCT Data 
beginning at question 32. 

 
8    

gfedcb
IgG not tested

  
 
IgG:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 
9  Date tested: __ __ __ __ - __ __- __ __  

 
 
10    

gfedcb
IgM not tested

  
 
IgM:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 
11  Date tested: __ __ __ __ - __ __- __ __  

 
 
12    

gfedcb
IgA not tested

  
 
IgA:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 
13  Date tested: __ __ __ __ - __ __- __ __  

 
 
14    

gfedcb
IgE not tested

 
 
IgE:    IU/mL 

 
 
15  Date tested: __ __ __ __ - __ __- __ __  

 
 

16  Did the recipient receive supplemental intravenous immunoglobulins (IVIG) since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

17  Was therapy ongoing within one month of immunoglobulin testing?

    
 nmlkji

yes  
 nmlkji

no  

 

Lymphocyte Analysis 

Specify the most recent lymphocyte assessment measured since the date of the last report. 

 
18  Were lymphocyte analyses performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 
19  Date of most recent testing performed: __ __ __ __ - __ __- __ __  

 
 
20  Absolute lymphocyte count:    cells / ul (cells / mm3) 

 
 
21    

gfedcb
CD3 not tested

 
 

CD3 (T cells) % of total lymphocytes    % 

  - or -  

  
 
CD3 (T cells) value    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
22    

gfedcb
CD4 (T helper cells) not tested

 
 

CD4 (T helper cells) % of total lymphocytes    % 

  - or -  

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 12



  
 
CD4 (T helper cells) value    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
23    

gfedcb
CD8 (cytotoxic T cells) not tested

 
 

CD8 (cytotoxic T cells) % of total lymphocytes    % 

  - or -  

  
 
CD8 (cytotoxic T cells) value    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
24    

gfedcb
CD20 (B lymphocyte cells) not tested

 
 

CD20 (B lymphocyte cells) % of total lymphocytes    % 

  - or -  

  
 
CD20 (B lymphocyte cells) value    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
25    

gfedcb
CD56 (natural killer (NK) cells) not tested

 
 

CD56 (natural killer (NK) cells) % of total lymphocytes    % 

  - or -  

  
 
CD56 (natural killer (NK) cells) value    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
26    

gfedcb
CD4+/CD45RA+ (memory T cells) not tested

 
 

CD4+/CD45RA+ (naive T cells) % of total lymphocytes    % 

  - or -  

  
 
CD4+/CD45RA+ (naive T cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
27    

gfedcb
CD4+/CD45RO+ (memory T cells) not tested

 
 

CD4+/CD45RO+ (memory T cells) % of total lymphocytes    % 

  - or -  

  
 
CD4+/CD45RO+ (memory T cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

Antibody Response 

Specify the most recent antibody responses measured since the date of the last report. 

 
28  Date antibody responses were assessed: __ __ __ __ - __ __- __ __  

 
 

29  Bacteriophage phi X-174 or other neoantigen

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

30  Diptheria

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

31  Isohemagglutinin anti-A

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 12



 
 

32  Isohemagglutinin anti-B

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

33  Protein conjugated HIB or pneumococcal vaccine

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

34  Tetanus

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

  
 

35  Unconjugated pneumococcal polysaccharide:      / 

    
Number of serotypes  

producing a protective level 

 
.    

   /Total serotypes tested from vaccine 

  
 

36  Conjugated pneumococcal polysaccharide:       / 

    
Number of serotypes  

producing a protective level 

 
   

  /Total serotypes tested from vaccine 

 

Lymphocyte Function 

Specify the most recent lymphocyte function measured since the date of the last report. 

 
37  Date lymphocyte function was assessed: __ __ __ __ - __ __- __ __  

 
 

38  Anti-CD3

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

39  Candida antigen

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

40  Concavalin A (ConA)

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

41  Phytohemagglutinin (PHA)

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 12



 
 

42  Pokeweed mitogen (PWM)

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

43  Tetanus antigen

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 

Infections Identified Post-HSCT 

Specify the presence of all clinically significant infections identified since the date of the last report. If any given infection was identified, use the Codes for Commonly Reported 

Organisms to report the organism present. Only report an organism once, even if it was identified at the same site in subsequent infections. 

Also report infections in the Form 2100 – 100 Days Post-HSCT Data beginning at question 379, or in the Form 2200 — Six Months to Two Years Post-HSCT Data beginning at 
question 319. 

 
44  Site of infection: hepatitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
45  Organism:   

 
 
46  Specify other organism:    

 
 
47  If hepatitis was present, was it a prominent feature of ID?

 nmlkji
yes  

 nmlkji
no  

 
 

48  Meningitis / encephalitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
49  Organism:   

 
 
50  Specify other organism:    

 
 

51  If meningitis / encephalitis was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 
 

52  Site of infection: pneumonia

    
 nmlkji

yes  
 nmlkji

no  

 
 
53  Organism:   

 
 
54  Specify other organism:    

 
 

55  If pneumonia was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

  Clinical Features Assessed Post-HSCT Questions: 44 - 94

  Hepatitis-Organism (1) Questions: 45 - 46 

  Meningitis/Encephalitis-Organism (1) Questions: 49 - 50 

  Pneumonia-Organism (1) Questions: 53 - 54 

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 12



 
 

56  Site of infection: severe or protracted diarrhea

    
 nmlkji

yes  
 nmlkji

no  

 
 
57  Organism:   

 
 
58  Specify other organism:    

 
 

59  If diarrhea was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 
 

60  Site of infection: systemic infection

    
 nmlkji

yes  
 nmlkji

no  

 
 
61  Organism:   

 
 
62  Specify other organism:    

 
 

63  If systemic infection was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 
 

64  Site of infection: other infection

    
 nmlkji

yes  
 nmlkji

no  

 
 
65  Organism:   

 
 
66  Specify other organism:    

 
 
67  Specify other infection site:    

 
 

68  If other infection was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 

Clinical Status Post-HSCT 
 

69  Did the recipient experience any of the following clinical features (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify clinical features: 
 

70  Autoimmune hemolytic anemia

    
 nmlkji

yes  
 nmlkji

no  

 
 

71  Is autoimmune hemolytic anemia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

72  Is failure to thrive (weight<5th percentile) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

73  Is failure to thrive (weight<5th percentile) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

74  Is acute graft versus host disease present?

    
 nmlkji

yes  
 nmlkji

no  

  Severe/protracted diarrhea-Organism (1) Questions: 57 - 58 

  Systemic infection-Organism (1) Questions: 61 - 62 

  Other infection-Organism (1) Questions: 65 - 66 

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 12



 
 

75  Is acute graft versus host disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

76  Is chronic graft versus host disease present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

77  Is chronic graft versus host disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

78  Is growth hormone deficiency present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

79  Is growth hormone deficiency prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

80  Is growth retardation (height<5th percentile) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

81  Is growth retardation (height<5th percentile) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

82  Is lymphoproliferative disease present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  Is lymphoproliferative disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  Is thrombotic thrombocytopenic purpura present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

85  Is thrombotic thrombocytopenic purpura prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

86  Is Veno-occlusive disease (VOD) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

87  Is Veno-occlusive disease (VOD) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

88  Are warts present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

89  Are warts prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

90  Are other clinical features present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

91  Are other clinical features prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 
92  Specify other clinical features:    

 
 

93  Did the recipient receive parenteral nutrition (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

94  Did the recipient receive mechanical ventilation (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 12



 
 

95  Was treatment given (since the date of the report)?

    
 nmlkji

yes  
 nmlkji

no  

 

Also report immunosuppressive medications given to prevent or treat GVHD in the corresponding questions on the Form 2000-Recipient Baseline Data, Form 2100-100 

Days Post-HSCT Data, Form 2200-Six Month to Two Years Post-HSCT Data, or Form 2300-Yearly Follow-Up for Greater Than Two Years Post-HSCT Data. 

Prophylactic drugs paused for < 1 week should not be considered as "Prophylactic Drug Stopped." 

 
96  Were antifungal drug(s) given as prophylaxis?

    
 nmlkji

yes  
 nmlkji

no  

 
 

97  Were prophylactic antifungal drug(s) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
98  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date prophylactic antifungal drug(s) stopped: __ __ __ __ - __ __- __ __  

 
 

99  Were antiviral drug(s) given as prophylaxis?

    
 nmlkji

yes  
 nmlkji

no  

 
 

100  Were prophylactic antiviral drug(s) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
101  

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date prophylactic antiviral drug(s) stopped: __ __ __ __ - __ __- __ __  

 
 

102  Was co-trimoxazole (Bactim, Septra) given as prophylaxis?

    
 nmlkji

yes  
 nmlkji

no  

 
 

103  Were co-trimoxazole (Bactrim, Septra) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
104  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date co-trimoxazole (Bactrim, Septra) stopped: __ __ __ __ - __ __- __ __  

 

Therapy paused for < 1 week shoudl not be considered "Therapy Stopped." 
 

105  Was antithymocyte globulin (ATG, ATGAM, Thymoglobulin) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

106  Was antithymocyte globulin (ATG, ATGAM, Thymoglobulin) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
107  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date antithymocyte globulin (ATG, ATGAM, Thymoglobulin) stopped: __ __ __ __ - __ __- __ __  

 
 

108  Were systemic corticosteroids given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

109  Were therapeutic systemic corticosteroids stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
110  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic systemic corticosteroids stopped: __ __ __ __ - __ __- __ __  

  Post-HSCT Treatment for Immune Deficiency Questions: 95 - 166

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 12



 
 

111  Were topical corticosteroids given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

112  Were therapeutic topical corticosteroids stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
113  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic topical corticosteroids stopped: __ __ __ __ - __ __- __ __  

 
 

114  Was cyclophosphamide (CTX, Cytoxan, Neosar) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

115  Was therapeutic cyclophosphamide (CTX, Cytoxan, Neosar) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
116  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic cyclophosphamide (CTX, Cytoxan, Neosar) stopped: __ __ __ __ - __ __- __ __  

 
 

117  Was cyclosporine (CsA, Neoral, Sandimmune) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

118  Was therapeutic cyclosporine (CsA, Neoral, Sandimmune) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
119  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic cyclosporine (CsA, Neoral, Sandimmune) stopped? __ __ __ __ - __ __- __ __  

 
 

120  Was in vivo monoclonal antibody given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify monoclonal antibody: 

 
121  Was alemtuzumab (Campath) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

122  Was therapeutic alemtuzumab (Campath) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
123  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic alemtuzumab (Campath) stopped: __ __ __ __ - __ __- __ __  

 
 

124  Was daclizumab (anti-CD25, Zenapax) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

125  Was therapeutic daclizumab (anti-CD25, Zenapax) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
126  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic daclizumab (anti-CD25, Zenapax) stopped: __ __ __ __ - __ __- __ __  

 
 

127  Was etanercept (Enbrel) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

128  Was therapeutic etanercept (Enbrel) stopped?

    
 nmlkji

yes  
 nmlkji

no  

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 12



 
 
129  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic etanercept (Enbrel) stopped: __ __ __ __ - __ __- __ __  

 
 

130  Was infliximab (anti-TNF-α, Remicade) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

131  Was therapeutic infliximab (anti-TNF-α, Remicade) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
132  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic infliximab (anti-TNF-α, Remicade) stopped: __ __ __ __ - __ __- __ __  

 
 

133  Was muromonab (anti-CD3, OKT3) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

134  Was therapeutic muromonab (anti-CD3, OKT3) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
135  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic muromonab (anti-CD3, OKT3) stopped: __ __ __ __ - __ __- __ __  

 
 

136  Was rituximab (anti-CD20, Rituxan, Mab Thera) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

137  Was therapeutic rituximab (anti-CD20, Rituxan, Mab Thera) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
138  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic rituximab (anti-CD20, Rituxan, Mab Thera) stopped: __ __ __ __ - __ __- __ __  

 
 

139  Was any other monoclonal antibody given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

140  Was therapeutic other monoclonal antibody stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
141  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic other monoclonal antibody stopped: __ __ __ __ - __ __- __ __  

 
 
142  Specify other monoclonal antibody:    

 
 

143  Was lenalidomide (Revlimid) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

144  Was therapeutic lenalidomide (Revlimid) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
145  

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic lenalidomide (Revlimid) stopped: __ __ __ __ - __ __- __ __  

 
 

146  Was mycophenolate mofetil (MMF, Cellcept) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

147  Was therapeutic mycophenolate mofetil (MMF, Cellcept) stopped?

    
 nmlkji

yes  
 nmlkji

no  

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 10 / 12



 
 
148  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic mycophenolate mofetil (MMF, Cellcept) stopped: __ __ __ __ - __ __- __ __  

 
 

149  Was photopheresis / extracorporeal phototherapy (ECP)given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

150  Was therapeutic photopheresis / extracorporeal phototherapy (ECP) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
151  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic photopheresis / extracorporeal phototherapy (ECP) stopped: __ __ __ __ - __ __- __ __  

 
 

152  Was sirolimus (Rapamune) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

153  Was therapeutic sirolimus (Rapamune) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
154  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic sirolimus (Rapamune) stopped: __ __ __ __ - __ __- __ __  

 
 

155  Was tacrolimus (FK506, Prograf) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

156  Was therapeutic tacrolimus (FK506, Prograf) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
157  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic tacrolimus (FK506, Prograf) stopped: __ __ __ __ - __ __- __ __  

 
 

158  Was thalidomide (Thalomid) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

159  Was therapeutic thalidomide (Thalomid)stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
160  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date therapeutic thalidomide (Thalomid)stopped: __ __ __ __ - __ __- __ __  

 
 

161  Was any other immunosuppressive drug given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

162  Was the other therapeutic immunosuppressive drug stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
163  .

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
Date other therapeutic immunosuppressive drug stopped: __ __ __ __ - __ __- __ __  

 
 
164  Specify other immunosuppressive drug:    

 
 

165  Did the recipient receive any other significant treatment(s) for ID (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

 
 
166  Specify other treatment(s):    

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 11 / 12



 

This section refers to quantitative analyses utilizing discriminating DNA markers. Peripheral blood cells must undergo seperation or sorting into T, B, or lymphoid vs. myeloid 

populations to perform this determination. If RFLP analyses indicate only donor type hemotopoiesis, mark T-cell, B-cell, and myeloid as "predominantly or completely donor." 

Also, report chimerism in the Form 2100-100 Days Post-HSCT Data beginning at question 77 or Form 2200-Six Months to Two Years Post-HSCT Data beginning at question 48. 

 
167  What is the current status of T-cell engraftment?

    
 nmlkji

predominantly or completely donor (>= 80% donor chimerism)  

 nmlkji
Mixed chimerism  

 nmlkji
only host T-cells detected (< 5% donor)  

 nmlkji
Unknown  

  
 
168  Most recent date T-cell engraftment was assessed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of most recent T-cell engraftment assessment unknown

 
 

169  What is the current status of B-cell engraftment?

    
 nmlkji

predominantly or completely donor (>= 80% donor chimerism)  

 nmlkji
Mixed chimerism  

 nmlkji
only host B-cells detected (< 5% donor)  

 nmlkji
Unknown  

  
 
170  Most recent date B-cell engraftment was assessed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of most recent B-cell engraftment assessment unknown?

 
 

171  What is the current status of myeloid engraftment?

    
 nmlkji

predominantly or completely donor (>= 80% donor chimerism)  

 nmlkji
Mixed chimerism  

 nmlkji
only host myeloid cells detected (< 5% donor)  

 nmlkji
Unknown  

  
 
172  Most recent date myeloid engraftment was assessed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of most recent myeloid engraftment assessment unknown

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

  Status of Hematologic Engraftment Questions: 167 - 172

Form 2131 R3.0: Immune Deficiencies Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2131 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 12 / 12